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Abstract: Super-enhancers (SEs) are clusters of highly active enhancers, regulating cell type-specific
and disease-related genes, including oncogenes. The individual regulatory regions within SEs might
be simultaneously bound by different transcription factors (TFs) and co-regulators, which together
establish a chromatin environment conducting to effective transcription. While cells with distinct
TF profiles can have different functions, how different cells control overlapping genetic programs
remains a question. In this paper, we show that the construction of estrogen receptor alpha-driven
SEs is tissue-specific, both collaborating TFs and the active SE components greatly differ between
human breast cancer-derived MCF-7 and endometrial cancer-derived Ishikawa cells; nonetheless,
SEs common to both cell lines have similar transcriptional outputs. These results delineate that
despite the existence of a combinatorial code allowing alternative SE construction, a single master
regulator might be able to determine the overall activity of SEs.
Keywords: estrogen receptor alpha (ERα); transcription factor; enhancer; super-enhancer; MCF-7
cell line; Ishikawa cell line; ChIP-seq
1. Introduction
Estrogen receptor alpha (ERα) is a well-studied member of the nuclear receptor (NR) superfamily
and functions as a master regulator in several cell types, including breast, ovarian, and endometrial
cancer cells [1–3]. The continuously changing level of its natural ligand, 17β-estradiol (E2),
is indispensable for maintaining the ovarian cycle, and although normal hormone levels are
responsible for female characteristics and contribute to healthy bone density among others, a higher
estrogen/progesterone ratio in breast and endometrial tissues is linked to an increased risk of breast
and endometrial cancer in postmenopausal women [4–6].
DNA binding by the receptor/ligand complex can occur directly through the estrogen response
element (ERE) or via indirect protein-protein interactions [7–11]. According to previous studies, nearly
one million EREs occur in the human genome, but only a small fraction of these EREs are located
within open chromatin regions [12,13]. In addition, the number of EREs bound by ERα is reduced
because the affinity of ERα for different EREs exhibits a broad spectrum [14]. High-affinity elements or
canonical elements can immobilize the transcription factor (TF), thus exerting a much greater influence
on gene expression than the weaker elements that most likely need other stabilizing TFs to generate
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the activator complex or indirect DNA-protein interactions where an association with other TFs is
required [15,16].
In the vicinity of highly expressed genes, multiple TFs are recruited to activate clusters of enhancers
within a relatively small stretch of DNA, which are also known as super-enhancers (SEs) or clustered
enhancers [17,18]. SEs can be characterized by a combination of active and open chromatin/enhancer
marks, such as DNase I hypersensitivity, recruitment of the histone acetyltransferase P300, histone
modifications such as acetylation at the lysine 27 residue of the histone H3 protein (H3K27ac),
the chromatin modification reader BRD4 (a member of the bromodomain and extraterminal (BET)
domain family) that recognizes acetylated histones, and MED1, which is one of the most important
subunits of the Mediator complex that has a bridging role between enhancers and promoters via
chromatin looping [19–21]. Recent studies reinforced that BRD4 and MED1 condensate at SEs in cell
nuclei, and SE condensates can be isolated by liquid-liquid phase separation [22,23]. Interestingly,
these protein clusters are assembled in a non-canonical way through the intrinsically disordered
domains of their constituents, highlighting the importance of non-classical domain-based protein
interactions, although according to several studies, SEs are located within CTCF-demarcated chromatin
domains [24–27]. This phenomenon indicates that SEs concentrate the most important co-activator
proteins, which distinguish them from typical enhancers. Although SEs can make physical contact
with their target promoters from very long distances, these are mostly identified near cell type-specific
or disease-related genes, which act as determinants of cell identity [17,24]. As suggested by several
studies on cancer cells, SEs contribute to the expression of relevant biomarker genes that might be
used for targeted therapeutic development; however, numerous questions regarding their exact gene
regulatory functions remain unanswered [28,29].
We previously presented that the formation of ligand-inducible ERα-driven SEs depends on the
presence of canonical EREs, which can initiate further ERα binding events at nearby and even less
specific binding sites [15,16]. These primary “mother” or “hub” enhancers (a term coined by Huang
et al.) represent active chromatin regions even in the absence of specific treatment, and these form
the basis of ligand-inducible SEs [30]. In the present study, we investigated whether (i) ERα-driven
SEs develop around the same canonical elements or in the same genomic regions in different cancer
cell lines, and also studied (ii) the common and (iii) cell line-specific characteristics of these SEs.
Furthermore, we examined in detail whether (iv) the effect of SEs on gene expression is equivalent in
two inherently different cancer cell lines. In order to answer these questions, by using publicly available
chromatin immunoprecipitation followed by sequencing (ChIP-seq) data, we predicted ERα-driven
SEs in human breast cancer-derived MCF-7 and endometrial cancer-derived Ishikawa cell lines in
which ERα is a key master regulator. We raised the possibility that comprehensive characterization of
cell line-specific ERα-driven gene regulatory units may also be important in understanding how ERα,
as a master TF can fine-tune different cell functions in a way that a core set of SEs can retain the same
function with different regulatory elements in different tissues.
2. Results
2.1. General Comparison of the Putative ERα Binding Sites in MCF-7 and Ishikawa Cells
Comparing different cell types, enhancers show an extremely high level of variability [31].
By testing the similarities between MCF-7 and Ishikawa cells at the level of ERα cistromes upon E2
treatment, we found that both cell lines had tens of thousands of ERα transcription factor binding
sites (TFBSs), but most of these sites were characteristic of only one of the investigated cell lines
(Figure 1A). This cell line-specific and overlapping ERα binding pattern is also followed by the presence
of H3K27ac signals suggesting that there is a large difference between the chromatin accessibility in the
two investigated cell lines (Figure 1B). In line with this result, EREs, which were commonly occupied
by ERα in both cell lines, showed the highest motif scores, followed by those of MCF-7-specific and
then Ishikawa-specific sites (Figure 1C). Based on our previous findings, these results suggest that a
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subset of EREs among commonly used EREs might be considered common nucleating sites of SEs
and in Ishikawa cells, the lower affinity of ERα-occupied EREs requires the assistance of collaborating
factors [15,16].
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Figure 1. Genome-wide comparison of ERα cistromes and transcriptomes in MCF-7 and Ishikawa 
cells upon E2 treatment. (A) Area-proportional Venn diagram showing the overlap between all ERα 
TFBSs upon E2 treatment in MCF-7 and Ishikawa cells. (B) Read distribution plots showing the 
presence or absence of the identified cell line-specific and overlapping ERα TFBSs and the H3K27ac 
signals in 2-kb frames. (C) Box plots showing the ERE motif strength within the summit ±100-bp 
region of the shared and cell line-specific TFBSs, defined in Figure 1A. The boxes represent the first 
and third quartiles, the lines indicate the median scores and the whiskers indicate the 10th to 90th 
percentile ranges. Unpaired t-test, **** significant at p <0.0001. 
2.2. ERα-driven SE Constituents have Different Motif Preferences in MCF-7 and Ishikawa Cells 
In accordance with the preliminary findings showing that a subset of enhancers are commonly 
occupied by ERα in both cell lines, we narrowed our focus on how ERα-driven SEs in different TF 
environments are assembled; therefore, we assessed ERα binding sites at the SE regions specific for 
MCF-7 and Ishikawa cells. Importantly, some studies define SEs based on H3K27ac or MED1 signals; 
here we consider this approach based on the binding density of ERα. We predicted 392 SE regions in 
MCF-7 and 618 in the Ishikawa cell line respectively, and most of their constituents were 
characteristic of only one investigated cell line (Figure 2A, Supplementary Figures S1A, B, 
Supplementary Table S1A). The cell line-specific, ERα-driven SE constituents were ~3.4 times more 
abundant in MCF-7 (n = 3,872) and ~1.9 times more abundant in Ishikawa (n = 2,138) cells than those 
present in both cell lines (n = 1,124) (Figure 2A, Supplementary Figure S1B). The presence of DNase I 
hypersensitivity, H3K27ac and P300 also followed the three well-separated binding patterns 
(Supplementary Figure S1C, Supplementary Table S1B). The resulted “clusters” were referred to as: 
(1) MCF-7-specific, (2) shared, as they are common to both cell types, and (3) Ishikawa-specific, 
highlighted if possible in blue, purple, and red, respectively, in the figures. 
The first substantial difference observed between the three identified clusters was seen in their 
enriched DNA motifs (Figure 2B, Supplementary Figure S1D). Within the commonly occupied TFBSs, 
only the ERE and different direct repeats (DRs) of the nuclear receptor half-site (NR half) were 
enriched, whereas, in the cell line-specific clusters, motifs of other TFs could also be identified. 
Specifically, motifs of the Fox and AP2 proteins were enriched in the MCF-7-specific cluster, and 
motifs of the TEAD, TCF, AP-1, and SIX proteins were enriched in the Ishikawa-specific cluster. The 
latter cluster did not show enrichment of the ERE motif but only the more general NR half-site, which 
suggests that in the Ishikawa-specific sites ERα needs the assistance of its co-factor(s). 
In MCF-7 cells, in addition to ERα, forkhead box A1 (FoxA1) is the most influential TF and is 
present in approximately half of ERα-bound genomic regions even in the absence of E2 [32,33]. FoxA1 
plays a role as a pioneer factor of ERα, thus facilitating its binding, while activator protein 2 gamma 
(AP2γ), another major TF, stabilizes the DNA-protein interaction [34]. Although GATA binding 
Figure 1. Genome-wide comparison of ERα cistromes and transcriptomes in MCF-7 and Ishikawa cells
upon E2 treatment. (A) Area-proporti nal Ve n diagram showing the overlap b tween all ERα TFBSs
upon E2 treatment in MCF-7 and Ishikawa cells. (B) Read distribution plots showing the prese ce or
abs nce of the id tified cell line-sp cific and overlapping ERα TFBSs and the H3K27 c signals in 2-kb
frames. (C) Box plots showing the ERE motif strength within the ummit ±100-bp region of the shared
and cell line-specific TFBSs, defi d in Figure 1A. The boxes represent the first and third quar iles, the
lines indicate the median scores and th whisk rs i di ate the 10th to 90th perce tile ranges. Unpaired
t-t st, **** sig ificant at p <0.0001.
2.2. ERα-driven SE Constituents have Different Motif Preferences in MCF-7 and Ishikawa Cells
In accordance with the preliminary findings showing that a subset of enhancers are commonly
occupied by ERα in both cell lines, we narrowed our focus on how ERα-driven SEs in different TF
environments are assembled; therefore, we assessed ERα binding sites at the SE regions specific for
MCF-7 and Ishikawa cells. Importantly, some studies define SEs based on H3K27ac or MED1 signals;
here we consider this approach based on the binding density of ERα. We predicted 392 SE regions in
MCF-7 and 618 in the Ishikawa cell line respectively, and most of their constituents were characteristic
of only one investigated cell line (Figure 2A, Supplementary Figure S1A,B and Table S1A). The cell
line-specific, ERα-driven SE constituents were ~3.4 times more abundant in MCF-7 (n = 3872) and
~1.9 times more abundant in Ishikawa (n = 2138) cells than those present in both cell lines (n = 1124)
(Figure 2A, Supplementary Figure S1B). The presence of DNase I hypersensitivity, H3K27ac and P300
also followed the three well-separated binding patterns (Supplementary Figure S1C and Table S1B).
The resulted “clusters” were referred to as: (1) MCF-7-specific, (2) shared, as they are common to
both cell types, and (3) Ishikawa-specific, highlighted if possible in blue, purple, and red, respectively,
in the figures.
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Figure 2. ERα-driven super-enhancer constituents show distinct binding patterns and motif 
preferences in MCF-7 and Ishikawa cells. (A) Read distribution plot showing ERα density on ERα-
driven super-enhancer (SE) constituents derived from MCF-7 and Ishikawa cells in 2-kb frames. Peaks 
were sorted based on the ratio of RPKM (reads per kilobase per million mapped reads) values 
calculated from Ishikawa and MCF-7 cells and were separated into three different clusters: the red 
line represents Ishikawa-specific constituents (n = 2,138), the purple line represents shared 
constituents (n = 1,124), and the blue line represents MCF-7-specific SE constituents (n = 3,872). (B) 
The enriched motifs and their percentages within the target regions of the three clusters. (C) The motif 
distribution plot of ERE, Fox, AP2, TCF, TEAD, and SIX motifs in 1.5-kb frames around the summit 
position of ERα-driven SE constituents in the same order as introduced in Figure 2A (middle). 
Colored heat maps represent shared and cell line-specific clusters when peaks were further clustered 
based on the presence or absence of the most frequent motifs. (D) Box plots showing the distribution 
of motif strengths within the three main clusters introduced in Figure 2A. The boxes represent the 
first and third quartiles, the horizontal lines indicate the median scores and the whiskers indicate the 
10th to 90th percentile ranges. Paired t-test, * significant at p < 0.05, ** at p < 0.01, *** at p < 0.001, **** at 
p < 0.0001. 
Generally, motif strengths correlated well with motif distribution patterns; however, TEAD 
motifs did not show significantly different motif strengths between the analyzed clusters (p > 0.05; 
not significant). These results indicated that the two cell lines use different sets of TFs and that motif 
distribution within SEs may represent a DNA-encoded component of SE-driven transcription 
regulation. 
2.3. Response Elements Determine the Hierarchy between FoxM1/TCF12/TEAD4 Proteins in Ishikawa Cells 
As TF motifs may be bound by several proteins of a TF family, we compared the expression 
levels of all members of the emerging TF families from publicly available RNA-seq data sets. In 
addition to FOXA1 and TFAP2C (encoding AP2γ), ESR1 (encoding ERα) also showed much lower 
expression in Ishikawa cells than in MCF-7 cells. This result is consistent with the less prominent 
dominance of ERα in Ishikawa cells than in MCF-7 cells and partially consistent with substitution or 
supplementation of its function by other TFs (Figure 1B). Of the more than 40 members of the Fox 
family, FOXM1 had the highest expression in Ishikawa cells; however, FOXD1 also showed a notable 
expression level (Supplementary Figures S3A, B, Supplementary Table S1B). Based on previous 
studies, in Ishikawa cells, forkhead box M1 (FoxM1) and CCAAT/enhancer-binding protein beta 
(C/EBPβ) were also described as potential regulatory partners of ERα [38]. Although the C/EBP motif 
– similarly to the Fox motif – is not a typical component of ERα-driven SEs, previous studies suggest 
that C/EBPβ can stabilize ERα in a DNA binding complex; therefore, we plotted the gene expression 
levels of the whole gene family (Supplementary Figure S3C) [44]. TCF12 and TEAD4 showed higher 
expression in Ishikawa cells than in MCF-7 cells, but this pattern was also observed for other family 
members, such as TCF3 and TEAD2. Although SIX genes were expressed at low levels in both cell 
lines, SIX5 was expressed at higher levels in Ishikawa cells, and SIX4 was specific to MCF-7 cells. Of 
all these genes, CEBPB showed the highest expression, and the genomic distribution of its protein 
product as investigated by TF mapping followed the binding pattern of ERα even in the absence of 
Figure 2. ERα-driven super-enhancer constituents show distinct binding patterns and motif preferences
in MCF-7 and Ishikawa cells. (A) Read distribution plot showing ERα density on ERα-driven
super-enhancer (SE) constituents derived from MCF-7 and Ishikawa cells in 2-kb frames. Peaks were
sorted based on the ratio of RPKM (reads per kilobase per million mapped reads) values calculated
from Ishikawa and MCF-7 cells and were separated into three different clusters: the red line represents
Ishikawa-specific constituents (n = 2138), th purple line repr sents shared co stituents (n = 1124),
and the blue line represe ts MCF-7-specific SE constituents (n = 3872). (B) The enriched motifs and
their percentages within the target regions of the three clusters. (C) The motif distribution plot of ERE,
Fox, AP2, TCF, TEAD, and SIX motifs in 1.5-kb frames around the summit position of ERα-driven SE
constituents in the same order as introduced in Figure 2A (middle). Colored heat maps represent shared
and cell line-specific clusters when peaks were further clustered based on the presence or absence of
the most frequent motifs. (D) Box plots showing the distribution of motif strengths within the three
main clusters introduced in Figure 2A. The boxes represent the first and third quartiles, the horizontal
lines indicate the median scores and the whiskers indicate the 10th to 90th percentile ranges. Paired
t-test, * significant at p < 0.05, ** at p < 0.01, *** at p < 0.001, **** at p < 0.0001.
The first substantial difference observed between the three identified clusters was seen in their
enriched DNA motifs (Figure 2B, Supplementary Figure S1D). Within the commonly occupied TFBSs,
only the ERE and different direct repeat (DRs) of the uclear rece tor half-site (NR half) were enriched,
whereas, in the cell line-specific clusters, motifs of other TFs could also be identified. Specifically,
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motifs of the Fox and AP2 proteins were enriched in the MCF-7-specific cluster, and motifs of the
TEAD, TCF, AP-1, and SIX proteins were enriched in the Ishikawa-specific cluster. The latter cluster
did not show enrichment of the ERE motif but only the more general NR half-site, which suggests that
in the Ishikawa-specific sites ERα needs the assistance of its co-factor(s).
In MCF-7 cells, in addition to ERα, forkhead box A1 (FoxA1) is the most influential TF and is
present in approximately half of ERα-bound genomic regions even in the absence of E2 [32,33]. FoxA1
plays a role as a pioneer factor of ERα, thus facilitating its binding, while activator protein 2 gamma
(AP2γ), another major TF, stabilizes the DNA-protein interaction [34]. Although GATA binding protein
3 (GATA3) and retinoic acid receptor alpha (RARα) were also identified as ERα cooperative factors in
breast cancer cells, these were not identified as crucial players in our investigations on ERα-driven
SEs [15,35–37].
All TF families that had their motifs enriched at the sites bound by ERα identified in Ishikawa cells
were previously directly associated with ERα in endometrial cancer [38]. TEA domain transcription
factor 4 (TEAD4) cooperates with activator protein 1 (AP-1) in the chromatin of endometrial cancer
cells and establishes an interaction between ERα and progesterone receptor (PR) in breast cancer
cells [39,40], transcription factor 12 (TCF12), also known as HEB, functions as an oncogene as well
as a tumor suppressor in several human cancer types [41]. In mouse experiments, TCF12 was also
identified as a key prognostic factor for endometrial cancer [42]. Although all of the above-mentioned
endometrial cancer-related proteins follow the binding of ERα in Ishikawa cells, there are no reports on
these proteins regarding ERα-driven SEs. Furthermore, the elevated expression of SIX1 is a biomarker
of hyper- or dysplastic cells in human endometrial cancers [43]. The exclusivity of the motifs in the
cell line-specific clusters suggested a different mode of action between the SEs and the assembled TF
complexes of our two chosen models where ERα is present as a master regulator.
Based on these initial findings, we carried out a detailed investigation of how different TFs
contribute to the formation of both cell line-specific and shared ERα-driven SEs. First, for validation,
we mapped the matrix of the identified DNA motifs and found that the shared ERα binding sites showed
large numbers of ERE and smaller numbers of other elements, whereas the cell line-specific enhancers
showed expected motif distribution patterns: Fox and AP2 motifs were enriched at MCF-7-specific
ERα binding sites, while TCF, TEAD, and SIX motifs were enriched at Ishikawa-specific ERα binding
sites (Figure 2C, Supplementary Figure S2A). Further dividing the three clusters based on motif
distribution showed that certain motifs (e.g., ERE and TEAD or Fox and AP2) mutually exclude each
other (Figure 1C). In order to examine the strengths of the enriched motifs, we plotted the motif scores
within the cell line-specific and shared clusters (Figure 2D, Supplementary Figure S2B).
Generally, motif strengths correlated well with motif distribution patterns; however, TEAD
motifs did not show significantly different motif strengths between the analyzed clusters (p > 0.05;
not significant). These results indicated that the two cell lines use different sets of TFs and that motif
distribution within SEs may represent a DNA-encoded component of SE-driven transcription regulation.
2.3. Response Elements Determine the Hierarchy between FoxM1/TCF12/TEAD4 Proteins in Ishikawa Cells
As TF motifs may be bound by several proteins of a TF family, we compared the expression levels
of all members of the emerging TF families from publicly available RNA-seq data sets. In addition to
FOXA1 and TFAP2C (encoding AP2γ), ESR1 (encoding ERα) also showed much lower expression in
Ishikawa cells than in MCF-7 cells. This result is consistent with the less prominent dominance of ERα
in Ishikawa cells than in MCF-7 cells and partially consistent with substitution or supplementation of
its function by other TFs (Figure 1B). Of the more than 40 members of the Fox family, FOXM1 had
the highest expression in Ishikawa cells; however, FOXD1 also showed a notable expression level
(Supplementary Figure S3A,B and Table S1B). Based on previous studies, in Ishikawa cells, forkhead
box M1 (FoxM1) and CCAAT/enhancer-binding protein beta (C/EBPβ) were also described as potential
regulatory partners of ERα [38]. Although the C/EBP motif—similarly to the Fox motif—is not a
typical component of ERα-driven SEs, previous studies suggest that C/EBPβ can stabilize ERα in a
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DNA binding complex; therefore, we plotted the gene expression levels of the whole gene family
(Supplementary Figure S3C) [44]. TCF12 and TEAD4 showed higher expression in Ishikawa cells than
in MCF-7 cells, but this pattern was also observed for other family members, such as TCF3 and TEAD2.
Although SIX genes were expressed at low levels in both cell lines, SIX5 was expressed at higher levels
in Ishikawa cells, and SIX4 was specific to MCF-7 cells. Of all these genes, CEBPB showed the highest
expression, and the genomic distribution of its protein product as investigated by TF mapping followed
the binding pattern of ERα even in the absence of ligand treatment in Ishikawa cells (Supplementary
Figure S3D); therefore, we included it in additional analyses. In accordance with the absence of any
C/EBP motif enrichment in our previous results (Figure 2B, Supplementary Figure S1E), we could
not detect any C/EBP motif enrichment around the ERα SE constituents (Supplementary Figure S3E).
At these sites, similar to FoxM1, C/EBPβ may bind indirectly to the DNA through ERα or other DNA
binding collaborators less affected by E2 treatment. Together with all of the above-mentioned TFs,
C/EBPβ followed cell line-specific ERα binding patterns (Supplementary Figure S3D,F). The gene
expression comparison confirmed the role of collaborating TFs and highlighted FoxM1 as a TF with a
major role in Ishikawa cells.
In addition, by examining the overall binding of specific TFs to DNA as expressed in average
RPKM values per motif distribution-based sub-clusters defined in Figure 2C, we identified specific
patterns of protein co-occurrences. All TFs showed high density at their specific elements and to a
lesser extent, other TFs were also recruited, except for FoxA1 and AP2γ, which excluded each other’s
presence at MCF-7-specific sites (Figure 3A). Unsurprisingly, the recruitment of ERα upon E2 treatment
was observed in each sub-cluster even at binding sites that lacked ERE (Figure 3A, Supplementary
Table S1B).
In order to closely examine the protein-protein interactions suggested by these results, we
performed a correlation analysis on TF binding (Figure 3B). In Ishikawa cells, FoxM1 and TCF12
showed the strongest co-occurrence with each other and with TEAD4 and E2-induced ERα. Although
C/EBPβ could be detected at ERα-driven SE constituents, its density did not show any correlation
with ERα binding; instead, its density was correlated with the Ishikawa-related FoxM1/TCF12/TEAD4
protein trio. The correlation heat map for MCF-7 suggested more independent recruitment of key TFs.
In order to examine both protein-protein and DNA-protein concomitance, we plotted TF densities
at their putative TFBSs (Figure 3C, Supplementary Figure S4A,B). This type of representation clearly
visualized that different TFs show higher density at their own elements, and we also obtained
information about their co-occurrence with each other at the same genomic sites. In Ishikawa cells,
the presence of ERα correlated best with that of FoxM1, followed by co-occurrence with TCF12
and TEAD4. Pairwise comparisons suggested a FoxM1/TCF12, TCF12/TEAD4, and FoxM1/TEAD4
interaction, which implies a tripartite complex interacting with ERα (Figure 3C,D, Supplementary
Figure S4A,B). The TCF12/TEAD4 relationship was also reproduced even with lower protein levels
in MCF-7 cells (r = 0.8833) (Supplementary Figure S4B). C/EBPβ binding showed no or only weak
correlation (r = 0.3489) with other TFs except for FoxM1; however, the low number of response elements
could cause a bias towards their interaction (Supplementary Figure S4A). Contact between a steroid
hormone receptor and Fox protein is not unprecedented as androgen receptor (AR) and FoxA1 associate
to occupy ARE::Fox composite elements. However, a single ARE or Fox motif is usually sufficient for
binding by both proteins [45–47]. In our proposed mechanism, any TF can bind its DNA element, and
this process is sufficient for anchoring the entire complex of proteins. As Ishikawa-specific Fox motifs
are very rare (as shown on Figure 2C), FoxM1 is typically not a direct DNA binder. This finding also
indicates no need for direct DNA binding by ERα for regulation in Ishikawa cells (unlike our previously
described finding in MCF-7 cells) (Figure 3A,B). In MCF-7 cells, there was no close correlation between
dominant proteins, and ERα/FoxA1 concomitances seemed to be the least frequent (r = 0.3626). Upon
E2 treatment, we observed a slight recruitment of FoxA1 and stronger recruitment of AP2γ, which
was previously described (Supplementary Figure S4B). In a few TFBSs, two motifs could be mapped
(green dots); these regions were usually bound by their specific TFs to a similar extent.
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Figure 3. Response elements determine a consistent hierarchy between transcription factor binding
events. (A) Heat maps depict the density of relevant TFs in the presence (+) or absence (−) of E2 within
the same sub-clusters introduced in Figure 2C. The plotted densities are the averages of the values
calculated by HOMER within 50-bp regions around the summit of the sub-clusters’ SE constituents.
In the case of shared peaks, ChIP-seq coverages were separately calculated for both Ishikawa and
MCF-7 cells. (B) Correlation plots showing the correlation coefficients (r) calculated from the densities
of all investigated TFs on the SE constituents (summit ± 50-bp regions) of Ishikawa and MCF-7 cells.
(C) Scatter plots showing the densities of the indicated TFs (upon vehicle [veh] or E2 treatment) on
their DNA binding motifs within the MCF-7- or Ishikawa-specific ERα-driven SE constituents. Red and
blue dots represent protein binding on a specific single motif, and green dots represent protein binding
on a region with the motifs of both examined TFs. (D) Working models of the supposed hierarchy
between ERα, FoxM1, TCF12, and TEAD4 TFs in Ishikawa cells based on the presence of ERE, TCF,
or TEAD response elements.
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Together, these findings indicated that TF binding events followed the DNA motif pattern and that
well-defined cooperativity and hierarchy existed between TFs promoting the formation of complexes
on SEs.
2.4. Overlapping SE Regions Are Composed of Different ERα Binding Sites
By focusing on complete ERα-driven SE regions, we found 99 SEs that partly or fully overlapped
between MCF-7 and Ishikawa cells. Nonetheless, these “common” SEs shared only a quarter of their
ERαTFBSs (410 in total) (Figure 4A,B, Supplementary Figure S5A). This heterogeneity of SE composition,
which was also observed at the WWC1 locus, suggests a strong cell type- and TF-specific enhancer
usage. For instance, despite its lower expression in MCF-7 cells, TCF12 was significantly recruited to
the central constituent of the SE, carrying an ERE and TCF motif (Figure 4C,D). This representative
region clearly demonstrated how Ishikawa-specific factors localized together and how their TFBSs
were separated from those of MCF-7-specific TFs (Figure 4D). Moreover, in Ishikawa cells, ERα mostly
occupied binding sites together with its collaborating factors. By contrast, in MCF-7 cells, ERα binding
events were much more isolated.
In order to measure the extent of ERα autonomy, we compared the number of SE constituents
bound by at least two collaborating TFs that were present in MCF-7 or Ishikawa cells (Figure 4E). Within
the 99 shared SEs, 47% of MCF-7-specific and 25% of Ishikawa-specific SE constituents were bound by
a maximum of one TF other than ERα, which implies that in Ishikawa cells ERα typically requires
several collaborating TFs for effective binding, while in MCF-7 cells this is optional. Another tendency
observed at the WWC1 locus was the opposed binding strength between ERα and its collaborating
factors in Ishikawa cells (Figure 4C,D). In order to test this finding, we sorted protein densities by the
ratio of ERα and TEAD4 signals (Supplementary Figure S5B). Indeed, the strongest ERα peaks were
mostly established on EREs and typically lacked collaborating factors, while co-occurrence with strong
cofactor binding resulted in moderate recruitment of ERα. This was in agreement with the results
of correlation analyses, indicating the significance of DNA-protein and protein-protein interactions
(Figure 3C, Supplementary Figure S4A). In the case of MCF-7-specific TFs, we observed a high ratio of
direct ERE binding and a positive correlation between protein enrichments (Supplementary Figure S5C).
Altogether, these results also supported our model (Figure 3D), showing that DNA binding by even
one of the examined TFs was able to promote the recruitment of other TFs that might be part of a cell
line-specific protein complex.
In general, we found only one or two putative response element(s) per peak, and in some cases,
none of the motif matrices used could be identified (Figure 4C). Within the common SE regions, the
shared binding sites were dominated by ERE alone (27%) or in combination with other motifs (21%,
concomitant presence of multiple motifs) and NR half-sites (14%) (Figure 5A,B). MCF-7-specific ERα
binding sites showed a similar motif distribution but had a considerably higher proportion of NR
half-sites (24%) and other motifs (29%). Alternatively, in Ishikawa cells, compared to ERE, TEAD (15%),
TCF (10%), and NR half motifs (15%) dominated (Figure 5A,B). Notably, Ishikawa-specific SEs were
typically bound by ERα at EREs not only in Ishikawa but also in MCF-7 cells, whereas MCF-7-specific
SEs were poorly bound in Ishikawa cells (Supplementary Figure S6A,B). This result is consistent with
the notion that while ERα is dominantly recruited to EREs or NR half-sites in MCF-7 cells, in Ishikawa
cells ERα can also be recruited by TEAD4 and/or TCF12 (Figure 5A,B).
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Notably, the annotation of regulatory sites to proper genes represents a limitation to any study
without using e.g., 3C-based methods, and we did not consider transient gene induction events.
According to the main characteristic of SEs (these cause high expression), an asymmetric distribution
pattern shifted to MCF-7-specific genes was observed for MCF-7-specific SEs. Nevertheless, several
genes showed similar gene expression in both cell lines (<2-fold difference), and a number of genes
showed higher expression in Ishikawa cells than in MCF-7 cells (>2-fold difference), although the
enhancers’ coverage by ERα was not high enough to call them SEs in Ishikawa cells (Figure 6A).
The high expression in Ishikawa cells around MCF-7-specific SEs might be due to the presence or
absence of different factors (e.g., repressors) or even technical difficulties in SE prediction or gene
annotation. A similar phenomenon with an opposite pattern in SE occupancy and gene expression
output was also observed for Ishikawa-specific SE-related genes (Figure 6C), genes regulated by shared
SEs showed similarly high expression in MCF-7 and Ishikawa cell lines, even though these had largely
different sets of collaborative factors (Figure 6B).
3. Discussion
As SEs are responsible for cell identity, understanding their mechanism of action is indispensable
for improving our knowledge of the regulation of gene expression in general and cellular identity
in particular [24]. The recruitment and activation of a dominant TF represents a key step in the
formation of SEs, and this recruitment is largely determined by the presence of specific DNA sequences.
In addition to these DNA sequences, also known as motifs, which will later result in TF binding, the
activating complexes are generated from gathered TFs; moreover, these complexes and protein-DNA
interactions are stabilized by additional protein-protein interactions [15].
Previous studies focused mostly on changes in SEs during differentiation; here we examined
how SE regions driven by the same master TF behave in two different cancer cell lines. We identified
392 ERα-driven SEs from the breast cancer-derived MCF-7 cells and 618 ERα-driven SEs from the
endometrial cancer-derived Ishikawa cells. By examining their unique components, the first evidence
was that despite a small overlapping subset, which likely involves conserved binding sites driven
by strong EREs, cell type-specific sites indicated the presence of quite different TF binding motifs.
These motifs were indeed bound by their recognition proteins, and through protein-protein interactions,
some of them have a great affinity for each other. Moreover, certain TF partners might make ERα a
hormone-sensitive coregulator, which increases TF binding affinity upon ligand treatment. However,
additional investigations using, for example, mass spectrometry, protein interaction assays, and
structural biochemical techniques are needed to identify all major components and oligomers of these
cell line-specific complexes.
Although in the MCF-7 cell line ERα-dominated SEs are also modulated by the well-known FoxA1
and AP2γ TFs, as described previously, ERα has no coequal TF partner. In Ishikawa cells, we assumed
the existence of at least a tripartite protein complex composed of TEAD4, TCF12, FoxM1, or C/EBPβ
in which FoxM1 might have the highest affinity for ERα. However, the role of FoxM1 might be only
secondary without its own response elements, and there can be additional TFs playing roles in the
assembled regulatory complexes. Of course, the overall structure of a complex based on ChIP-seq
data cannot be determined, and further specific experiments supporting this model should be applied.
In this study, we carried out a theoretical investigation by using a large publicly available data set
derived from two cell lines; however, the proteins identified based on their DNA motifs are indeed
parts of a complex acting at SEs and some of them (TEAD4 or TCF12) might have a so-far unknown
pioneer role.
Out of the predicted 392 (MCF-7) and 618 (Ishikawa) ERα-driven SEs, only 99 regions overlapped
in the two cell lines where ERα was recruited in an alternating fashion, depending on the presence of
cell line-specific co-factors and their motif(s). In Ishikawa cells, three-quarters of these ERα binding sites
required the presence of at least two collaborative factors. By contrast, in MCF-7 cells, only half of the
binding sites showed the presence of both FoxA1 and AP2γ or even TEAD4/TCF12. This observation
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may be explained by ERα binding directly to DNA through the ERE, and FoxA1 or AP2γ rather
facilitates and/or stabilizes their presence in MCF-7 cells. By contrast, in Ishikawa cells, except for strong
canonical EREs, ERα binding occurs almost exclusively through DNA binding collaborating factors.
Overall, we observed that depending on the expressed collaborating TFs, ERα behaves in very different
ways. One strong ERE might be sufficient for ERα binding but it is basically insufficient for regulation.
Nearby motifs—even within the same enhancer or distant ones within the enhancer cluster—will
determine the functional ERα TFBSs, and ultimately the whole cistrome. These results explain how
gene regulation is carried out by a combination of DNA sequences selected by a combination of
expressed TFs. This is a two-level combinatorial code of regulation further supported by specific
co-regulators establishing permissive chromatin environment and chromatin interactions.
Overall, the results confirm the importance of the examined SE-bound genomic regions and the
genes affected by them. MCF-7-specific ERα-driven SEs indeed regulated genes with pivotal roles in
breast cancer (e.g., BCAS3, as an amplified and overexpressed gene and ZNF217, the candidate organizer
of repressive histone modifiers) (highlighted in blue in Supplementary Figure S7A) and altered the
expression of genes regulated by Ishikawa-specific SEs, which were typically specific for endometrial
cancer (e.g., ANXA2 and ATF4) (highlighted in red in Supplementary Figure S7B) [48–51]. However,
some genes were not specifically associated with these two tumor types, but it may be assumed that
these play important roles as they are regulated by SEs. Importantly, the genes regulated by common
SEs showed similar expression patterns in both MCF-7 and Ishikawa cells even though these were
supported by different collaborating factors and most of these commonly regulated genes are associated
with poor prognosis or metastatic conditions (e.g., AZIN1, KRT8, KRT19, SLC9A3R1, HES1, and CXXC5),
further demonstrating the importance of understanding the function of strong/canonical regulatory
elements or complete units, such as SEs (highlighted in grey in Supplementary Figure S7C) [52–54].
Our results suggest that cell type-specific SEs regulate genes with high expression levels, and most of
these are indeed linked to (breast and/or endometrial) cancerous processes. Furthermore, the complete
or partial deletion of these units may influence the expression of oncogenes so these can be targets of
future investigations.
Although several studies reported that different cell types had different transcription profiles
and specific TF pools, the essence of our hypothesis is that in different cell types, shared SEs can
generate very similar transcriptional events even though these shared SEs are built from various
individual enhancers based on the cell type-specific TF profile. Our proposal is that these shared SEs
have DNA-encoded responsiveness towards different subsets of TFs, and these behave like bona fide
multi-tools of the genome.
Our study has several limitations. The results rely on the super-enhancer-regulated genomic
regions, not the whole genome is studied; and the cancer cell lines used for the study are not tested to
copy number alterations. In addition, instead of early and transient gene expression changes that are
difficult to handle, we focused on maintained, steady-state gene expression levels upon a longer period
of time in both cell lines. In order to verify the presented cell-type-specific protein-protein interactions
further biochemical and genomic methods are required. One of the major limitations of the study is
that our bioinformatic investigations were performed on breast- and endometrial cancer cell lines.
For a better understanding of the tissue specificity of SEs, animal studies would be needed.
Besides the limitations highlighted, we believe that our investigations provide a new level of
understanding of the plasticity of transcription regulation with potential clinical implications. Based on
the presented results, further investigations can be initiated that could widen our understanding of
the effects and side-effects of hormonal treatments in these two endocrine dependent tissues, namely
breast and endometrium, both of these being of major interest in women’s health.
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4. Materials and Methods
4.1. Data Selection
Raw ChIP-seq, DNase-seq, and RNA-seq data were downloaded from the Gene Expression
Omnibus (GEO). As we used data from ECC-1 isolates of ATCC (American Type Culture Collection,
Manassas, VA, USA) that were genotyped as Ishikawa cells [55]; we therefore referred to them as
Ishikawa cells. Detailed information about the selected data (including GEO identifiers and references
for the publications where these were first published) is included in Supplementary Table S1A–C.
4.2. ChIP-seq Analysis
Raw sequence data were analyzed uniformly with an updated version of our previously published
computational pipeline [56] as follows: raw sequence reads were aligned to the hg19 reference genome
assembly (GRCh37) by using the Burrows-Wheeler Alignment (BWA) tool (v07.10) [57], then BAM files
were generated with SAMtools (v0.1.19) [58]. Coverage files were created by the makeUCSCfile.pl script
of the Hypergeometric Optimization of Motif EnRichment (HOMER) package (v4.2) [59], and peaks
were predicted using the Model-based Analysis of ChIP-Seq (MACS2) tool (v2.0.10) with -callpeak
parameter [60]. In order to remove the artifacts from the predicted peaks, we used the blacklisted
genomic regions of the Encyclopedia of DNA Elements (ENCODE) [61].
Reads Per Kilobase per Million mapped reads (RPKM) values were calculated on the ±50-bp
regions relative to the peak summits by using the coverageBed program of BedTools (v2.23.0) [62].
The number of overlapping peaks and regions was defined by using the DiffBind package (v1.2.4) in
R [63]. Read distribution (RD) heat maps were generated by annotatePeaks.pl with -hist 50 and -ghist
parameters (HOMER). Coverage values for average protein density heat maps were calculated on the
summit positions of the RD plots.
4.3. Super-Enhancer Prediction
Super-enhancers were predicted from the E2-treated ERαChIP-seq samples applying the HOMER’s
findPeaks.pl script and the -style super parameter. In order to generate a “super-enhancer plot”, we used
the -superSlope -1000 parameter and the thus generated “Normalized Tag Count” values were plotted.
Tag counts (rpm/bp; reads per million per base pair) of the ERα (super-)enhancers were ranked by
their ChIP-seq coverage. The definition of super-enhancers was based on the original strategy, where
the outstandingly “active” enhancers or broader regions in which enhancers are closer than 12.5 kb to
each other are over slope 1 in the rank order.
4.4. Motif Analysis
Motif enrichment analysis was carried out by the findMotifsGenome.pl script of HOMER. It was
performed on the ±100 bp flanking regions of the peak summits. The lengths for the motif search were
10, 12, 14, and 16 bp. p-values were calculated by comparing the enrichment within the target regions
and that of a random set of regions (background) generated by HOMER.
For the motif distribution plot, motif matrices (shown in Supplementary Figure S2A) were mapped
in 30-bp windows within 1.5-kb frames relative to the ERα peak summits using annotatePeaks.pl with
-mbed parameter, BEDtools, and other command-line programs. The clustering of motif distribution
patterns was done by Cluster 3.0. The top motif score for each examined region was determined by
annotatePeaks.pl with -mscore parameter. Thresholds of the plotted scores were selected before the last
markedly high peak of the motif score distribution.
4.5. DNase-seq Analysis
The primary analysis of DNase-seq data was carried out as described for ChIP-seq data analysis.
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4.6. RNA-seq Analysis
Raw sequence reads were aligned to the hg19 reference genome assembly (GRCh37) by using
TopHat (v2.0.7). The Fragments Per Kilobase of transcript per Million mapped reads (FPKM) values
were calculated by Cufflinks (v2.0.2) with default parameters [64].
4.7. Gene Annotation
Super-enhancers were extended to ±100-kb relative to their center. The highest expressed
protein-coding gene (at 240 and 320 min of E2 treatment of Ishikawa and MCF-7 cells, respectively) the
promoter of which overlapped with an extended region was assigned to the related super-enhancer.
If an extended region could not be annotated to any gene, the closest protein-coding gene with at least
1 FPKM expression value was assigned to it by using the PeakAnnotator program [65].
4.8. Visualization
Read distribution, average protein density, and correlation heat maps were plotted by Java
TreeView (v1.1.6r4) [66]. Area-proportional Venn diagrams were produced by BioVenn [67]. Box plots,
scatter plots, bar charts, and histograms were created with GraphPad Prism 6. Coverage files were
visualized by Integrative Genomics Viewer v2.4.16 (IGV) [68].
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Author Contributions: B.L.B., D.B., and G.N. designed the study. D.B. collected and analysed the data. D.B. and
G.N. carried out the detailed computational analysis and wrote the manuscript. B.L.B. revised the analysis and
wrote the manuscript, and all authors have read and agreed to the published version of the manuscript.
Funding: This work is supported by the internal research funding provided by the Department of Biochemistry
and Molecular Biology, University of Debrecen, Debrecen, Hungary. BLB is supported by the MOLMEDEX
FUN-OMICS (GINOP-2.3.3-15-2016-00007) and Debrecen Venture Catapult Program (EFOP-3.6.1-16-2016-00022)
grants implemented through the New Hungary Development Plan co-financed by the European Social Fund and the
European Regional Development Fund and by the Hungarian Scientific Research Fund (NKFIH OTKA) K 129166.
D.B. is supported by the ÚNKP-17-3-IV-DE-140 and ÚNKP-18-3-III-DE-253 New National Excellence Program
of the Ministry of Human Capacities and by the EFOP-3.6.3-VEKOP-16-2017-00009 grant. G.N. is supported
by the Hungarian Scientific Research Fund (OTKA) PD 124843, by the János Bolyai Research Scholarship of the
Hungarian Academy of Sciences and by the ÚNKP-19-4-DE-173 New National Excellence Program of the Ministry
of Human Capacities. The authors acknowledge the support of ELIXIR Hungary (www.elixir-hungary.org).
This study makes use of publicly-available sequencing data, which were cited in the manuscript.
Acknowledgments: The authors would like to thank István Szatmári for critical revision and comments on the
manuscript, Nature Research Editing Service for the language editing, and Balázs Venkovits (Institute of English
and American Studies, University of Debrecen, Hungary) for proofreading the manuscript prior to submission.
Conflicts of Interest: The authors declare no conflict of interest.
Abbreviations
ERα estrogen receptor alpha
ERE estrogen response element
E2 estradiol (17β-estradiol)




TFBS transcription factor binding site
Int. J. Mol. Sci. 2020, 21, 1630 15 of 18
References
1. Germain, P.; Staels, B.; Dacquet, C.; Spedding, M.; Laudet, V. Overview of nomenclature of nuclear receptors.
Pharmacol. Rev. 2006, 58, 685–704. [CrossRef] [PubMed]
2. Ross-Innes, C.S.; Stark, R.; Teschendorff, A.E.; Holmes, K.A.; Ali, H.R.; Dunning, M.J.; Brown, G.D.; Gojis, O.;
Ellis, I.O.; Green, A.R.; et al. Differential oestrogen receptor binding is associated with clinical outcome in
breast cancer. Nature 2012, 481, 389–393. [CrossRef] [PubMed]
3. Zhang, Y.; Zhao, D.; Gong, C.; Zhang, F.; He, J.; Zhang, W.; Zhao, Y.; Sun, J. Prognostic role of hormone
receptors in endometrial cancer: A systematic review and meta-analysis. World J. Surg. Oncol. 2015, 13, 208.
[CrossRef] [PubMed]
4. Reed, B.G.; Carr, B.R. The Normal Menstrual Cycle and the Control of Ovulation; MDText.com Inc.:
South Dartmouth, MA, USA, 2000.
5. Väänänen, H.K.; Härkönen, P.L. Estrogen and bone metabolism. Maturitas 1996, 23, S65–S69. [CrossRef]
6. Groothuis, P.G.; Dassen, H.H.N.M.; Romano, A.; Punyadeera, C. Estrogen and the endometrium: Lessons
learned from gene expression profiling in rodents and human. Hum. Reprod. Update 2007, 13, 405–417.
[CrossRef] [PubMed]
7. Klein-Hitpass, L.; Schorpp, M.; Wagner, U.; Ryffel, G.U. An estrogen-responsive element derived from the
5’ flanking region of the Xenopus vitellogenin A2 gene functions in transfected human cells. Cell 1986,
46, 1053–1061. [CrossRef]
8. Kumar, V.; Chambon, P. The estrogen receptor binds tightly to its responsive element as a ligand-induced
homodimer. Cell 1988, 55, 145–156. [CrossRef]
9. Klinge, C.M. Estrogen receptor interaction with co-activators and co-repressors. Steroids 2000, 65, 227–251.
[CrossRef]
10. Gaub, M.P.; Bellard, M.; Scheuer, I.; Chambon, P.; Sassone-Corsi, P. Activation of the ovalbumin gene by the
estrogen receptor involves the fos-jun complex. Cell 1990, 63, 1267–1276. [CrossRef]
11. Klinge, C.M. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res. 2001,
29, 2905–2919. [CrossRef]
12. Vega, V.B.; Lin, C.-Y.; Lai, K.S.; Kong, S.L.; Xie, M.; Su, X.; Teh, H.F.; Thomsen, J.S.; Yeo, A.L.; Sung, W.K.; et al.
Multiplatform genome-wide identification and modeling of functional human estrogen receptor binding
sites. Genome Biol. 2006, 7, R82. [CrossRef] [PubMed]
13. Joseph, R.; Orlov, Y.L.; Huss, M.; Sun, W.; Kong, S.L.; Ukil, L.; Pan, Y.F.; Li, G.; Lim, M.; Thomsen, J.S.; et al.
Integrative model of genomic factors for determining binding site selection by estrogen receptor-α. Mol. Syst.
Biol. 2010, 6, 456. [CrossRef] [PubMed]
14. Bourdeau, V.; Deschênes, J.; Métivier, R.; Nagai, Y.; Nguyen, D.; Bretschneider, N.; Gannon, F.; White, J.H.;
Mader, S. Genome-wide identification of high-affinity estrogen response elements in human and mouse.
Mol. Endocrinol. 2004, 18, 1411–1427. [CrossRef] [PubMed]
15. Bojcsuk, D.; Nagy, G.; Balint, B.L. Inducible super-enhancers are organized based on canonical signal-specific
transcription factor binding elements. Nucleic Acids Res. 2017, 45, 3699–3706. [CrossRef]
16. Bojcsuk, D.; Bálint, B.L. Classification of different types of estrogen receptor alpha binding sites in MCF-7
cells. J. Biotechnol. 2019, 299, 13–20. [CrossRef]
17. Lovén, J.; Hoke, H.A.; Lin, C.Y.; Lau, A.; Orlando, D.A.; Vakoc, C.R.; Bradner, J.E.; Lee, T.I.; Young, R.A.
Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013, 153, 320–334. [CrossRef]
18. Pott, S.; Lieb, J.D. What are super-enhancers? Nat. Genet. 2015, 47, 8–12. [CrossRef]
19. Kagey, M.H.; Newman, J.J.; Bilodeau, S.; Zhan, Y.; Orlando, D.A.; van Berkum, N.L.; Ebmeier, C.C.;
Goossens, J.; Rahl, P.B.; Levine, S.S.; et al. Mediator and cohesin connect gene expression and chromatin
architecture. Nature 2010, 467, 430–435. [CrossRef]
20. Di Micco, R.; Fontanals-Cirera, B.; Low, V.; Ntziachristos, P.; Yuen, S.K.; Lovell, C.D.; Dolgalev, I.; Yonekubo, Y.;
Zhang, G.; Rusinova, E.; et al. Control of embryonic stem cell identity by BRD4-dependent transcriptional
elongation of super-enhancer-associated pluripotency genes. Cell Rep. 2014, 9, 234–247. [CrossRef]
21. Tsai, C.-J.; Nussinov, R. Gene-specific transcription activation via long-range allosteric shape-shifting.
Biochem. J. 2011, 439, 15–25. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 1630 16 of 18
22. Sabari, B.R.; Dall’Agnese, A.; Boija, A.; Klein, I.A.; Coffey, E.L.; Shrinivas, K.; Abraham, B.J.; Hannett, N.M.;
Zamudio, A.V.; Manteiga, J.C.; et al. Coactivator condensation at super-enhancers links phase separation
and gene control. Science 2018, 361, eaar3958. [CrossRef] [PubMed]
23. Hnisz, D.; Shrinivas, K.; Young, R.A.; Chakraborty, A.K.; Sharp, P.A. A phase separation model for
transcriptional control. Cell 2017, 169, 13–23. [CrossRef] [PubMed]
24. Hnisz, D.; Abraham, B.J.; Lee, T.I.; Lau, A.; Saint-André, V.; Sigova, A.A.; Hoke, H.A.; Young, R.A.
Super-enhancers in the control of cell identity and disease. Cell 2013, 155, 934–947. [CrossRef] [PubMed]
25. Siersbæk, R.; Baek, S.; Rabiee, A.; Nielsen, R.; Traynor, S.; Clark, N.; Sandelin, A.; Jensen, O.N.; Sung, M.-H.;
Hager, G.L.; et al. Molecular architecture of transcription factor hotspots in early adipogenesis. Cell Rep.
2014, 7, 1434–1442. [CrossRef] [PubMed]
26. Willi, M.; Yoo, K.H.; Reinisch, F.; Kuhns, T.M.; Lee, H.K.; Wang, C.; Hennighausen, L. Facultative CTCF
sites moderate mammary super-enhancer activity and regulate juxtaposed gene in non-mammary cells.
Nat. Commun. 2017, 8, 16069. [CrossRef]
27. Dowen, J.M.; Fan, Z.P.; Hnisz, D.; Ren, G.; Abraham, B.J.; Zhang, L.N.; Weintraub, A.S.; Schuijers, J.; Lee, T.I.;
Zhao, K.; et al. Control of cell identity genes occurs in insulated neighborhoods in mammalian chromosomes.
Cell 2014, 159, 374–387. [CrossRef]
28. Shin, H.Y. Targeting super-enhancers for disease treatment and diagnosis. Mol. Cells 2018, 41, 506–514.
29. Sengupta, S.; George, R.E. Super-enhancer-driven transcriptional dependencies in cancer. Trends Cancer 2017,
3, 269–281. [CrossRef]
30. Huang, J.; Li, K.; Cai, W.; Liu, X.; Zhang, Y.; Orkin, S.H.; Xu, J.; Yuan, G.-C. Dissecting super-enhancer
hierarchy based on chromatin interactions. Nat. Commun. 2018, 9, 943. [CrossRef]
31. Nord, A.S.; Blow, M.J.; Attanasio, C.; Akiyama, J.A.; Holt, A.; Hosseini, R.; Phouanenavong, S.; Plajzer-Frick, I.;
Shoukry, M.; Afzal, V.; et al. Rapid and pervasive changes in genome-wide enhancer usage during mammalian
development. Cell 2013, 155, 1521–1531. [CrossRef]
32. Carroll, J.S.; Liu, X.S.; Brodsky, A.S.; Li, W.; Meyer, C.A.; Szary, A.J.; Eeckhoute, J.; Shao, W.; Hestermann, E.V.;
Geistlinger, T.R.; et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range
regulation requiring the forkhead protein FoxA1. Cell 2005, 122, 33–43. [CrossRef] [PubMed]
33. Hurtado, A.; Holmes, K.A.; Ross-Innes, C.S.; Schmidt, D.; Carroll, J.S. FoxA1 is a key determinant of estrogen
receptor function and endocrine response. Nat. Genet. 2011, 43, 27–33. [CrossRef] [PubMed]
34. Tan, S.K.; Lin, Z.H.; Chang, C.W.; Varang, V.; Chng, K.R.; Pan, Y.F.; Yong, E.L.; Sung, W.K.; Sung, W.K.;
Cheung, E. AP-2γ regulates oestrogen receptor-mediated long-range chromatin interaction and gene
transcription. EMBO J. 2011, 30, 2569–2581. [CrossRef] [PubMed]
35. Ross-Innes, C.S.; Stark, R.; Holmes, K.A.; Schmidt, D.; Spyrou, C.; Russell, R.; Massie, C.E.; Vowler, S.L.;
Eldridge, M.; Carroll, J.S. Cooperative interaction between retinoic acid receptor- and estrogen receptor in
breast cancer. Genes Dev. 2010, 24, 171–182. [CrossRef] [PubMed]
36. Theodorou, V.; Stark, R.; Menon, S.; Carroll, J.S. GATA3 acts upstream of FOXA1 in mediating ESR1 binding
by shaping enhancer accessibility. Genome Res. 2013, 23, 12–22. [CrossRef] [PubMed]
37. Liu, Z.; Merkurjev, D.; Yang, F.; Li, W.; Oh, S.; Friedman, M.J.; Song, X.; Zhang, F.; Ma, Q.; Ohgi, K.A.;
et al. Enhancer activation requires trans-recruitment of a mega transcription factor complex. Cell 2014,
159, 358–373. [CrossRef] [PubMed]
38. Droog, M.; Nevedomskaya, E.; Kim, Y.; Severson, T.; Flach, K.D.; Opdam, M.; Schuurman, K.; Gradowska, P.;
Hauptmann, M.; Dackus, G.; et al. Comparative cistromics reveals genomic cross-talk between FoxA1 and
ER in tamoxifen-associated endometrial carcinomas. Cancer Res. 2016, 76, 3773–3784. [CrossRef]
39. Khushi, M.; Clarke, C.L.; Graham, J.D. Bioinformatic analysis of cis-regulatory interactions between
progesterone and estrogen receptors in breast cancer. Peer J. 2014, 2, e654. [CrossRef]
40. Liu, X.; Li, H.; Rajurkar, M.; Li, Q.; Cotton, J.L.; Ou, J.; Zhu, L.J.; Goel, H.L.; Mercurio, A.M.; Park, J.-S.; et al.
Tead and AP1 coordinate transcription and motility. Cell Rep. 2016, 14, 1169–1180. [CrossRef]
41. Chen, Q.; Liang, Y.; Zhang, Y.; Jiang, M.; Han, Z.; Liang, Y.; Wan, Y.; Yin, J.; He, H.-C.; Zhong, W. Decreased
expression of TCF12 contributes to progression and predicts biochemical recurrence in patients with prostate
cancer. Tumor Biol. 2017, 39, 101042831770392. [CrossRef]
42. Kompass, K.S.; Witte, J.S. Co-regulatory expression quantitative trait loci mapping: Method and application
to endometrial cancer. BMC Med. Genom. 2011, 4, 6. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2020, 21, 1630 17 of 18
43. Suen, A.A.; Jefferson, W.N.; Wood, C.E.; Padilla-Banks, E.; Bae-Jump, V.L.; Williams, C.J. SIX1 oncoprotein as
a biomarker in a model of hormonal carcinogenesis and in human endometrial cancer. Mol. Cancer Res. 2016,
14, 849–858. [CrossRef] [PubMed]
44. Stender, J.D.; Kim, K.; Charn, T.H.; Komm, B.; Chang, K.C.N.; Kraus, W.L.; Benner, C.; Glass, C.K.;
Katzenellenbogen, B.S. Genome-wide analysis of estrogen receptor alpha DNA binding and tethering
mechanisms identifies Runx1 as a novel tethering factor in receptor-mediated transcriptional activation.
Mol. Cell. Biol. 2010, 30, 3943–3955. [CrossRef] [PubMed]
45. Lupien, M.; Eeckhoute, J.; Meyer, C.A.; Wang, Q.; Zhang, Y.; Li, W.; Carroll, J.S.; Liu, X.S.; Brown, M. FoxA1
translates epigenetic Signatures into enhancer-driven lineage-specific transcription. Cell 2008, 132, 958–970.
[CrossRef] [PubMed]
46. Tewari, A.K.; Yardimci, G.; Shibata, Y.; Sheffield, N.C.; Song, L.; Taylor, B.S.; Georgiev, S.G.; Coetzee, G.A.;
Ohler, U.; Furey, T.S.; et al. Chromatin accessibility reveals insights into androgen receptor activation and
transcriptional specificity. Genome Biol. 2012, 13, R88. [CrossRef] [PubMed]
47. Sahu, B.; Laakso, M.; Pihlajamaa, P.; Ovaska, K.; Sinielnikov, I.; Hautaniemi, S.; Janne, O.A. FoxA1 Specifies
unique androgen and glucocorticoid receptor binding events in prostate cancer cells. Cancer Res. 2013,
73, 1570–1580. [CrossRef]
48. Bärlund, M.; Monni, O.; Weaver, J.D.; Kauraniemi, P.; Sauter, G.; Heiskanen, M.; Kallioniemi, O.-P.;
Kallioniemi, A. Cloning of BCAS3 (17q23) and BCAS4 (20q13) genes that undergo amplification,
overexpression, and fusion in breast cancer†. Genes Chromosom. Cancer 2002, 35, 311–317. [CrossRef]
49. Vendrell, J.A.; Thollet, A.; Nguyen, N.T.; Ghayad, S.E.; Vinot, S.; Bieche, I.; Grisard, E.; Josserand, V.; Coll, J.-L.;
Roux, P.; et al. ZNF217 is a marker of poor prognosis in breast cancer that drives epithelial-mesenchymal
transition and invasion. Cancer Res. 2012, 72, 3593–3606. [CrossRef]
50. Alonso-Alconada, L.; Santacana, M.; Garcia-Sanz, P.; Muinelo-Romay, L.; Colas, E.; Mirantes, C.; Monge, M.;
Cueva, J.; Oliva, E.; Soslow, R.A.; et al. Annexin-A2 as predictor biomarker of recurrent disease in endometrial
cancer. Int. J. Cancer 2015, 136, 1863–1873. [CrossRef]
51. Liu, B.; Chen, P.; Xi, D.; Zhu, H.; Gao, Y. ATF4 regulates CCL2 expression to promote endometrial cancer
growth by controlling macrophage infiltration. Exp. Cell Res. 2017, 360, 105–112. [CrossRef]
52. Silva, T.M.; Cirenajwis, H.; Wallace, H.M.; Oredsson, S.; Persson, L. A role for antizyme inhibitor in cell
proliferation. Amino. Acids 2015, 47, 1341–1352. [CrossRef] [PubMed]
53. Fang, L.; Wang, Y.; Gao, Y.; Chen, X. Overexpression of CXXC5 is a strong poor prognostic factor in ER+
breast cancer. Oncol. Lett. 2018, 16, 395–401. [CrossRef] [PubMed]
54. Tomaskovic-Crook, E.; Thompson, E.W.; Thiery, J.P. Epithelial to mesenchymal transition and breast cancer.
Breast Cancer Res. 2009, 11, 213. [CrossRef] [PubMed]
55. Korch, C.; Spillman, M.A.; Jackson, T.A.; Jacobsen, B.M.; Murphy, S.K.; Lessey, B.A.; Jordan, V.C.; Bradford, A.P.
DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and
contamination. Gynecol. Oncol. 2012, 127, 241–248. [CrossRef] [PubMed]
56. Barta, E. Command line analysis of ChIP-seq results. EMB Net. J. 2011, 17, 13–17. [CrossRef]
57. Li, H.; Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics
2009, 25, 1754–1760. [CrossRef]
58. Li, H.; Handsaker, B.; Wysoker, A.; Fennell, T.; Ruan, J.; Homer, N.; Marth, G.; Abecasis, G.; Durbin, R. 1000
genome project data processing subgroup the sequence alignment/map format and SAMtools. Bioinformatics
2009, 25, 2078–2079. [CrossRef]
59. Heinz, S.; Benner, C.; Spann, N.; Bertolino, E.; Lin, Y.C.; Laslo, P.; Cheng, J.X.; Murre, C.; Singh, H.; Glass, C.K.
Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for
macrophage and B cell identities. Mol. Cell 2010, 38, 576–589. [CrossRef]
60. Zhang, Y.; Liu, T.; Meyer, C.A.; Eeckhoute, J.; Johnson, D.S.; Bernstein, B.E.; Nusbaum, C.; Myers, R.M.;
Brown, M.; Li, W.; et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 2008, 9, R137. [CrossRef]
61. Dunham, I.; Kundaje, A.; Aldred, S.F.; Collins, P.J.; Davis, C.A.; Doyle, F.; Epstein, C.B.; Frietze, S.; Harrow, J.;
Kaul, R.; et al. An integrated encyclopedia of DNA elements in the human genome. Nature 2012, 489, 57–74.
62. Quinlan, A.R.; Hall, I.M. BEDTools: A flexible suite of utilities for comparing genomic features. Bioinformatics
2010, 26, 841–842. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2020, 21, 1630 18 of 18
63. Stark, R.; Brown, G. DiffBind: Differential Binding Analysis of ChIP- Seq Peak Data. Available online: https:
//bioconductor.statistik.tu-dortmund.de/packages/2.13/bioc/vignettes/DiffBind/inst/doc/DiffBind.pdf (accessed
on 22 February 2020).
64. Trapnell, C.; Williams, B.A.; Pertea, G.; Mortazavi, A.; Kwan, G.; van Baren, M.J.; Salzberg, S.L.; Wold, B.J.;
Pachter, L. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform
switching during cell differentiation. Nat. Biotechnol. 2010, 28, 511–515. [CrossRef] [PubMed]
65. Salmon-Divon, M.; Dvinge, H.; Tammoja, K.; Bertone, P. PeakAnalyzer: Genome-wide annotation of
chromatin binding and modification loci. BMC Bioinform. 2010, 11, 415. [CrossRef] [PubMed]
66. Saldanha, A.J. Java Treeview—Extensible visualization of microarray data. Bioinformatics 2004, 20, 3246–3248.
[CrossRef] [PubMed]
67. Hulsen, T.; de Vlieg, J.; Alkema, W. BioVenn—A web application for the comparison and visualization of
biological lists using area-proportional Venn diagrams. BMC Genom. 2008, 9, 488. [CrossRef] [PubMed]
68. Thorvaldsdottir, H.; Robinson, J.T.; Mesirov, J.P. Integrative genomics viewer (IGV): High-performance
genomics data visualization and exploration. Brief. Bioinform. 2013, 14, 178–192. [CrossRef] [PubMed]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
